CytoDyn Announces FDA Accepts Revised Rolling Review Timeline for Resubmission of its BLA


Management expects the non-clinical and CMC sections of the BLA to be resubmitted to FDA in November

See original here:
CytoDyn Announces FDA Accepts Revised Rolling Review Timeline for Resubmission of its BLA

Related Posts